Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „NSCLC“
Suchtreffer
Begriffe & Kennungen
Imfinzi · 4.8 · In resectable NSCLC patients in the AEGEAN study, some differences in safety were reported between elderly (≥
Eintrag öffnenKeytruda · 4.8 · In patients with NSCLC, pneumonitis occurred in 230 (6.1%), including Grade 2, 3, 4 or 5 cases in 103 (2.7%),
Eintrag öffnenKeytruda · 4.8 · In patients with NSCLC, pneumonitis occurred in 230 (6.1%), including Grade 2, 3, 4 or 5 cases in 103 (2.7%),
Eintrag öffnenMvasi · 4.8 · 18 In patients with NSCLC excluding predominant squamous histology, all grade reactions were seen with a frequ
Eintrag öffnenOpdivo · 4.8 · In the non-squamous NSCLC study (CA209057), the safety profile in patients with baseline renal or hepatic impa
Eintrag öffnenOpdivo · 4.8 · In the non-squamous NSCLC study (CA209057), the safety profile in patients with baseline renal or hepatic impa
Eintrag öffnenTagrisso · 4.8 · Studies in EGFR mutation-positive NSCLC patients
Eintrag öffnenTarceva · 4.8 · Interstitial lung disease (ILD) ILD includes fatalities in patients receiving Tarceva for treatment of NSCLC o
Eintrag öffnenTecentriq · 4.8 · 84 Use of atezolizumab in the adjuvant NSCLC setting
Eintrag öffnenTecentriq · 4.8 · In the first-line NSCLC study (IMpower150), an overall higher frequency of adverse events was observed in the
Eintrag öffnenTecentriq · 4.8 · In the first-line NSCLC study (IMpower150), an overall higher frequency of adverse events was observed in the
Eintrag öffnenTecentriq · 4.8 · The safety profile of atezolizumab in the adjuvant setting in the non-small cell lung cancer (NSCLC) patient p
Eintrag öffnenTecentriq · 4.8 · The safety profile of atezolizumab in the adjuvant setting in the non-small cell lung cancer (NSCLC) patient p
Eintrag öffnenTecentriq · 4.8 · Use of atezolizumab in the adjuvant NSCLC setting
Eintrag öffnenTevimbra · 4.8 · Pneumonitis occurred in 11.2% of patients with NSCLC treated with tislelizumab in combination with chemotherap
Eintrag öffnenXalkori · 4.8 · 24 Adult patients with NSCLC All-causality complex renal cysts were experienced by 52 (3%) of 1722 adult patie
Eintrag öffnenXalkori · 4.8 · Across studies in adult patients with either ALK-positive or ROS1-positive advanced NSCLC (N=1722), Grade 3 or
Eintrag öffnenXalkori · 4.8 · Adult patients with NSCLC Across studies in adult patients with either ALK-positive or ROS1-positive advanced
Eintrag öffnenXalkori · 4.8 · Adult patients with NSCLC Across studies in adult patients with either ALK-positive or ROS1-positive advanced
Eintrag öffnenXalkori · 4.8 · Adult patients with NSCLC Drug-induced hepatotoxicity with fatal outcome occurred in 0.1% of 1722 adult patien
Eintrag öffnen